Tumor therapy by gene regulation system responding to cellular signal

Tetsuro Tomiyama, Riki Toita, Jeong Hun Kang, Daisuke Asai, Shujiro Shiosaki, Takeshi Mori, Takuro Niidome, Yoshiki Katayama

研究成果: ジャーナルへの寄稿記事

10 引用 (Scopus)

抄録

For safe and efficient gene therapy, the development of gene delivery systems to specifically target tumor cells is one of the most important issues regarding present gene delivery methodologies. Recently, we have developed a novel drug or gene delivery system responding to cellular signals (D-RECS) that can activate transgenes in response to hyperactivated cellular signals. Especially, a protein kinase C (PKC)α-responsive polymeric carrier (polymer-peptide conjugate, PPC(S)) showed highly specific gene expression to tumor cells and tissues. In the present study, we have applied the PKCα-responsive polymeric carrier to tumor gene therapy. PPC(S) consists of a polyacrylamide backbone and cationic peptide side chains, which together make PPC(S) as a positive polymer, a PKCα-specific substrate. A negative control polymer, PPC(A), was also prepared by replacing a serine residue at the phosphorylation site of the peptide side chains of PPC(S) with alanine. A complex of PPC(S) with caspase-8 or the herpes simplex virus-thymidine kinase (HSV-TK) gene as therapeutic genes was transfected into certain tumor cells or tissues. The prodrug ganciclovir (GCV) was then intraperitoneally injected into PPC(S)/HSV-TK complex-transfected mice. The PPC(S)/gene complex showed significant cytotoxicity toward the tumor cells and suppression of tumor growth, compared with those of the PPC(A)/gene complex or PBS. These results indicate that the PKCα-responsive polymeric carrier is applicable for tumor-targeted gene therapy.

元の言語英語
ページ(範囲)101-105
ページ数5
ジャーナルJournal of Controlled Release
148
発行部数1
DOI
出版物ステータス出版済み - 11 20 2010

Fingerprint

Genetic Therapy
Protein Kinase C
Neoplasms
Gene Transfer Techniques
Polymers
Thymidine Kinase
Genes
Simplexvirus
Peptides
Ganciclovir
Caspase 8
Prodrugs
Drug Delivery Systems
Transgenes
Alanine
Serine
Phosphorylation
Gene Expression
Growth

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

これを引用

Tumor therapy by gene regulation system responding to cellular signal. / Tomiyama, Tetsuro; Toita, Riki; Kang, Jeong Hun; Asai, Daisuke; Shiosaki, Shujiro; Mori, Takeshi; Niidome, Takuro; Katayama, Yoshiki.

:: Journal of Controlled Release, 巻 148, 番号 1, 20.11.2010, p. 101-105.

研究成果: ジャーナルへの寄稿記事

Tomiyama, T, Toita, R, Kang, JH, Asai, D, Shiosaki, S, Mori, T, Niidome, T & Katayama, Y 2010, 'Tumor therapy by gene regulation system responding to cellular signal', Journal of Controlled Release, 巻. 148, 番号 1, pp. 101-105. https://doi.org/10.1016/j.jconrel.2010.08.017
Tomiyama, Tetsuro ; Toita, Riki ; Kang, Jeong Hun ; Asai, Daisuke ; Shiosaki, Shujiro ; Mori, Takeshi ; Niidome, Takuro ; Katayama, Yoshiki. / Tumor therapy by gene regulation system responding to cellular signal. :: Journal of Controlled Release. 2010 ; 巻 148, 番号 1. pp. 101-105.
@article{e2e2957cb9be4c7db2ab4f68ea0a6006,
title = "Tumor therapy by gene regulation system responding to cellular signal",
abstract = "For safe and efficient gene therapy, the development of gene delivery systems to specifically target tumor cells is one of the most important issues regarding present gene delivery methodologies. Recently, we have developed a novel drug or gene delivery system responding to cellular signals (D-RECS) that can activate transgenes in response to hyperactivated cellular signals. Especially, a protein kinase C (PKC)α-responsive polymeric carrier (polymer-peptide conjugate, PPC(S)) showed highly specific gene expression to tumor cells and tissues. In the present study, we have applied the PKCα-responsive polymeric carrier to tumor gene therapy. PPC(S) consists of a polyacrylamide backbone and cationic peptide side chains, which together make PPC(S) as a positive polymer, a PKCα-specific substrate. A negative control polymer, PPC(A), was also prepared by replacing a serine residue at the phosphorylation site of the peptide side chains of PPC(S) with alanine. A complex of PPC(S) with caspase-8 or the herpes simplex virus-thymidine kinase (HSV-TK) gene as therapeutic genes was transfected into certain tumor cells or tissues. The prodrug ganciclovir (GCV) was then intraperitoneally injected into PPC(S)/HSV-TK complex-transfected mice. The PPC(S)/gene complex showed significant cytotoxicity toward the tumor cells and suppression of tumor growth, compared with those of the PPC(A)/gene complex or PBS. These results indicate that the PKCα-responsive polymeric carrier is applicable for tumor-targeted gene therapy.",
author = "Tetsuro Tomiyama and Riki Toita and Kang, {Jeong Hun} and Daisuke Asai and Shujiro Shiosaki and Takeshi Mori and Takuro Niidome and Yoshiki Katayama",
year = "2010",
month = "11",
day = "20",
doi = "10.1016/j.jconrel.2010.08.017",
language = "English",
volume = "148",
pages = "101--105",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Tumor therapy by gene regulation system responding to cellular signal

AU - Tomiyama, Tetsuro

AU - Toita, Riki

AU - Kang, Jeong Hun

AU - Asai, Daisuke

AU - Shiosaki, Shujiro

AU - Mori, Takeshi

AU - Niidome, Takuro

AU - Katayama, Yoshiki

PY - 2010/11/20

Y1 - 2010/11/20

N2 - For safe and efficient gene therapy, the development of gene delivery systems to specifically target tumor cells is one of the most important issues regarding present gene delivery methodologies. Recently, we have developed a novel drug or gene delivery system responding to cellular signals (D-RECS) that can activate transgenes in response to hyperactivated cellular signals. Especially, a protein kinase C (PKC)α-responsive polymeric carrier (polymer-peptide conjugate, PPC(S)) showed highly specific gene expression to tumor cells and tissues. In the present study, we have applied the PKCα-responsive polymeric carrier to tumor gene therapy. PPC(S) consists of a polyacrylamide backbone and cationic peptide side chains, which together make PPC(S) as a positive polymer, a PKCα-specific substrate. A negative control polymer, PPC(A), was also prepared by replacing a serine residue at the phosphorylation site of the peptide side chains of PPC(S) with alanine. A complex of PPC(S) with caspase-8 or the herpes simplex virus-thymidine kinase (HSV-TK) gene as therapeutic genes was transfected into certain tumor cells or tissues. The prodrug ganciclovir (GCV) was then intraperitoneally injected into PPC(S)/HSV-TK complex-transfected mice. The PPC(S)/gene complex showed significant cytotoxicity toward the tumor cells and suppression of tumor growth, compared with those of the PPC(A)/gene complex or PBS. These results indicate that the PKCα-responsive polymeric carrier is applicable for tumor-targeted gene therapy.

AB - For safe and efficient gene therapy, the development of gene delivery systems to specifically target tumor cells is one of the most important issues regarding present gene delivery methodologies. Recently, we have developed a novel drug or gene delivery system responding to cellular signals (D-RECS) that can activate transgenes in response to hyperactivated cellular signals. Especially, a protein kinase C (PKC)α-responsive polymeric carrier (polymer-peptide conjugate, PPC(S)) showed highly specific gene expression to tumor cells and tissues. In the present study, we have applied the PKCα-responsive polymeric carrier to tumor gene therapy. PPC(S) consists of a polyacrylamide backbone and cationic peptide side chains, which together make PPC(S) as a positive polymer, a PKCα-specific substrate. A negative control polymer, PPC(A), was also prepared by replacing a serine residue at the phosphorylation site of the peptide side chains of PPC(S) with alanine. A complex of PPC(S) with caspase-8 or the herpes simplex virus-thymidine kinase (HSV-TK) gene as therapeutic genes was transfected into certain tumor cells or tissues. The prodrug ganciclovir (GCV) was then intraperitoneally injected into PPC(S)/HSV-TK complex-transfected mice. The PPC(S)/gene complex showed significant cytotoxicity toward the tumor cells and suppression of tumor growth, compared with those of the PPC(A)/gene complex or PBS. These results indicate that the PKCα-responsive polymeric carrier is applicable for tumor-targeted gene therapy.

UR - http://www.scopus.com/inward/record.url?scp=78649529322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649529322&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2010.08.017

DO - 10.1016/j.jconrel.2010.08.017

M3 - Article

C2 - 20727927

AN - SCOPUS:78649529322

VL - 148

SP - 101

EP - 105

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 1

ER -